Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2026-03-05 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for companies listed on the HKEX to report monthly movements in securities, including share capital, share options, and other equity changes. Since it is a recurring regulatory filing detailing changes in share capital and equity structure, it falls under the 'Regulatory Filings' category.
2026-03-05 English
VOLUNTARY ANNOUNCEMENT - SUGEMALIMAB RECEIVES UK MHRA APPROVAL FOR STAGE III NSCLC
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by CStone Pharmaceuticals regarding a regulatory approval (UK MHRA) for one of its products, sugemalimab. It provides business development updates, details about the drug, and a cautionary statement. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate regulatory announcement regarding business operations, it falls under the RNS (Regulatory Filings) category.
2026-02-23 English
UPDATE ON THE QUALIFICATION OF JOINT COMPANY SECRETARY AND CHANGE OF COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE
Board/Management Information Classification · 1% confidence The document is an official announcement from CStone Pharmaceuticals regarding the resignation of a joint company secretary and the appointment of a new authorized representative. This falls under the category of changes in senior management or board-related administrative roles, which is classified as MANG (Board/Management Information).
2026-02-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange. This is a standard regulatory filing required by the HKEX for listed companies to report monthly movements in securities, share capital, and share options. It does not fit into categories like Annual Reports, Earnings Releases, or M&A activity, but rather serves as a recurring regulatory disclosure of share capital changes. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-05 English
DATE OF BOARD MEETING AND NOTICE OF KEY BUSINESS UPDATES
Earnings Release Classification · 1% confidence The document is a short announcement (3,279 characters) from CStone Pharmaceuticals regarding the scheduling of a board meeting to approve annual results and providing notice of upcoming business updates and an investor conference call. It does not contain the actual financial results or the full report, but rather serves as a notification of the timing of these events. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) or a general regulatory announcement. Given the specific nature of announcing the date of a board meeting and future publication, RPA is the most accurate classification. FY 2025
2026-02-02 English
INSIDE INFORMATION ANNOUNCEMENT ON TRANSFER OF 100% EQUITY INTERESTS IN A WHOLLY-OWNED SUBSIDIARY THROUGH PUBLIC TENDER
M&A Activity Classification · 1% confidence The document is an official announcement from Yankuang Energy Group regarding the transfer of 100% equity interest in a subsidiary (Xintai Coal) through a public tender process. It details the transaction overview, valuation, bidding results, and potential impact on the company's financial performance. This falls under the category of M&A activity (divestiture/asset sale), which is classified as TAR.
2026-02-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.